399 related articles for article (PubMed ID: 36367195)
21. A reciprocal feedback between N6-methyladenosine reader YTHDF3 and lncRNA DICER1-AS1 promotes glycolysis of pancreatic cancer through inhibiting maturation of miR-5586-5p.
Hu Y; Tang J; Xu F; Chen J; Zeng Z; Han S; Wang F; Wang D; Huang M; Zhao Y; Huang Y; Zhuo W; Zhao G
J Exp Clin Cancer Res; 2022 Feb; 41(1):69. PubMed ID: 35183226
[TBL] [Abstract][Full Text] [Related]
22. Dysregulation of key microRNAs in pancreatic cancer development.
Baradaran B; Shahbazi R; Khordadmehr M
Biomed Pharmacother; 2019 Jan; 109():1008-1015. PubMed ID: 30551350
[TBL] [Abstract][Full Text] [Related]
23. Dual roles and therapeutic potential of Keap1-Nrf2 pathway in pancreatic cancer: a systematic review.
Qin JJ; Cheng XD; Zhang J; Zhang WD
Cell Commun Signal; 2019 Sep; 17(1):121. PubMed ID: 31511020
[TBL] [Abstract][Full Text] [Related]
24. Risk factors of pancreatic cancer and their possible uses in diagnostics.
Lang J; Kunovský L; Kala Z; Trna J
Neoplasma; 2021 Mar; 68(2):227-239. PubMed ID: 33350848
[TBL] [Abstract][Full Text] [Related]
25. Pancreatic cancer: medical aspects.
Okada S; Yoshimori M; Kakizoe T
Pancreas; 1998 Apr; 16(3):349-54. PubMed ID: 9548678
[TBL] [Abstract][Full Text] [Related]
26. Research advances of N6-methyladenosine in diagnosis and therapy of pancreatic cancer.
Chen S; Ren H; Zhang X; Chang L; Wang Z; Wu H; Zhang J; Ren J; Zhou L
J Clin Lab Anal; 2022 Sep; 36(9):e24611. PubMed ID: 35837987
[TBL] [Abstract][Full Text] [Related]
27. High risk factors of pancreatic carcinoma.
Camara SN; Yin T; Yang M; Li X; Gong Q; Zhou J; Zhao G; Yang ZY; Aroun T; Kuete M; Ramdany S; Camara AK; Diallo AT; Feng Z; Ning X; Xiong JX; Tao J; Qin Q; Zhou W; Cui J; Huang M; Guo Y; Gou SM; Wang B; Liu T; Olivier OET; Conde T; Cisse M; Magassouba AS; Ballah S; Keita NLM; Souare IS; Toure A; Traore S; Balde AK; Keita N; Camara ND; Emmanuel D; Wu HS; Wang CY
J Huazhong Univ Sci Technolog Med Sci; 2016 Jun; 36(3):295-304. PubMed ID: 27376795
[TBL] [Abstract][Full Text] [Related]
28. Long noncoding RNA CCDC26 as a potential predictor biomarker contributes to tumorigenesis in pancreatic cancer.
Peng W; Jiang A
Biomed Pharmacother; 2016 Oct; 83():712-717. PubMed ID: 27470572
[TBL] [Abstract][Full Text] [Related]
29. MicroRNA Targeted Therapeutic Approach for Pancreatic Cancer.
Li Y; Sarkar FH
Int J Biol Sci; 2016; 12(3):326-37. PubMed ID: 26929739
[TBL] [Abstract][Full Text] [Related]
30. Prospects of miRNA-based therapy for pancreatic cancer.
Pai P; Rachagani S; Are C; Batra SK
Curr Drug Targets; 2013 Sep; 14(10):1101-9. PubMed ID: 23834151
[TBL] [Abstract][Full Text] [Related]
31. Insights into the Role of microRNAs in Pancreatic Cancer Pathogenesis: Potential for Diagnosis, Prognosis, and Therapy.
Khan MA; Zubair H; Srivastava SK; Singh S; Singh AP
Adv Exp Med Biol; 2015; 889():71-87. PubMed ID: 26658997
[TBL] [Abstract][Full Text] [Related]
32. A Comprehensive Review of Diagnostic and Therapeutic Strategies for the Management of Pancreatic Cancer.
Sinha V; Shinde S; Saxena S; Thakur S; Walia T; Dixit V; Tiwari AK; Vishvakarma NK; Dwivedi M; Shukla D
Crit Rev Oncog; 2020; 25(4):381-404. PubMed ID: 33639064
[TBL] [Abstract][Full Text] [Related]
33. The Emerging Role of RNA N6-Methyladenosine Modification in Pancreatic Cancer.
Hu X; Lei X; Guo J; Fu W; Sun W; Lu Q; Su W; Xu Q; Tu K
Front Oncol; 2022; 12():927640. PubMed ID: 35936737
[TBL] [Abstract][Full Text] [Related]
34. Precursors of pancreatic cancer.
Frič P; Škrha J; Šedo A; Bušek P; Laclav M; Bunganič B; Zavoral M
Eur J Gastroenterol Hepatol; 2017 Mar; 29(3):e13-e18. PubMed ID: 28009716
[TBL] [Abstract][Full Text] [Related]
35. Pancreatic cancer: diagnosis and treatments.
Li HY; Cui ZM; Chen J; Guo XZ; Li YY
Tumour Biol; 2015 Mar; 36(3):1375-84. PubMed ID: 25680410
[TBL] [Abstract][Full Text] [Related]
36. Mucin-based targeted pancreatic cancer therapy.
Torres MP; Chakraborty S; Souchek J; Batra SK
Curr Pharm Des; 2012; 18(17):2472-81. PubMed ID: 22372499
[TBL] [Abstract][Full Text] [Related]
37. Osteoglycin (OGN) promotes tumorigenesis of pancreatic cancer cell via targeting ID4.
Qin W; Zhang J; Rong R; Zhang L; Gao H; Liu C; Ren Q; Zheng G; Wang J; Meng L; Qiao S; Qian R; Zhou C; Wang H; Zhang Y
Tissue Cell; 2022 Oct; 78():101867. PubMed ID: 35908351
[TBL] [Abstract][Full Text] [Related]
38. Combined modality treatments in pancreatic cancer.
Lombardi L; Troiano M; Silvestris N; Nanni L; Latiano TP; Di Maggio G; Cinieri S; Di Sebastiano P; Colucci G; Maiello E
Expert Opin Ther Targets; 2012 Apr; 16 Suppl 2():S71-81. PubMed ID: 22443336
[TBL] [Abstract][Full Text] [Related]
39. Targeting microRNAs in pancreatic cancer: microplayers in the big game.
Khan S; Ansarullah ; Kumar D; Jaggi M; Chauhan SC
Cancer Res; 2013 Nov; 73(22):6541-7. PubMed ID: 24204026
[TBL] [Abstract][Full Text] [Related]
40. Diagnostic and therapeutic approach to pancreatic adenocarcinoma.
Germanos S; Gourgiotis S; Stavrothanasopoulou A; Alepas P; Zampitis N; Panteli A
J Gastrointestin Liver Dis; 2006 Sep; 15(3):257-63. PubMed ID: 17013451
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
